Concord Biotech Overview

  • Year Founded
  • 1984

Year Founded

  • Status
  • Public

  • Employees
  • 2,401

Employees

  • Stock Symbol
  • 543960

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $25.50
  • (As of Monday Closing)

Concord Biotech General Information

Description

Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products.

Contact Information

Formerly Known As
Concord Control Systems Private Limited
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Mondeal Heights, Iscon Cross Road, S.G. Highway
  • 16th Floor, B-Wing
  • Ahmedabad, Gujarat 380015
  • India
+91 079
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
BOM
Corporate Office
  • Mondeal Heights, Iscon Cross Road, S.G. Highway
  • 16th Floor, B-Wing
  • Ahmedabad, Gujarat 380015
  • India
+91 079

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Concord Biotech Stock Performance

As of 10-Feb-2025, Concord Biotech’s stock price is $25.50. Its current market cap is $2.67B with 105M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$25.50 $26.74 $15.97 - $31.79 $2.67B 105M 5.81K $0.38

Concord Biotech Financials Summary

As of 30-Sep-2024, Concord Biotech has a trailing 12-month revenue of $128M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023 FY 2022 31-Mar-2022
EV 2,503,140 1,881,796
Revenue 127,960 120,559 103,444 95,083
EBITDA 59,212 56,250 46,840 38,689
Net Income 39,331 37,217 29,899 23,478
Total Assets 210,751 203,938 184,405 173,127
Total Debt 409 1,168 3,842 8,241
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Concord Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Concord Biotech‘s full profile, request access.

Request a free trial

Concord Biotech Patents

Concord Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170073374-A1 A process for isolation pf romidepsin from fermentation broth and preparation of crystals of romidepsin Active 04-Mar-2014
US-10294276-B2 Process for isolation of romidepsin from fermentation broth and preparation of crystals of romidepsin Active 04-Mar-2014
US-10119158-B2 Process for the preparation of fidaxomicin Active 23-Apr-2013
US-20160083764-A1 An improved process for the preparation of fidaxomicin Active 23-Apr-2013
US-20070142424-A1 Process for producing tacrolimus (fk-506) using vegetable oil as sole source of carbon Inactive 29-Jul-2004 C12P17/188
To view Concord Biotech’s complete patent history, request access »

Concord Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Concord Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Concord Biotech‘s full profile, request access.

Request a free trial

Concord Biotech Investments (1)

Concord Biotech’s most recent deal was a Corporate with CleanMax for . The deal was made on 16-Jan-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CleanMax 16-Jan-2025 Corporate Energy Production
To view Concord Biotech’s complete investments history, request access »

Concord Biotech ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Commercial Services

Industry

Rank

Percentile

Business Support Services

Subindustry

Rank

Percentile

To view Concord Biotech’s complete esg history, request access »

Concord Biotech FAQs

  • When was Concord Biotech founded?

    Concord Biotech was founded in 1984.

  • Where is Concord Biotech headquartered?

    Concord Biotech is headquartered in Ahmedabad, India.

  • What is the size of Concord Biotech?

    Concord Biotech has 2,401 total employees.

  • What industry is Concord Biotech in?

    Concord Biotech’s primary industry is Pharmaceuticals.

  • Is Concord Biotech a private or public company?

    Concord Biotech is a Public company.

  • What is Concord Biotech’s stock symbol?

    The ticker symbol for Concord Biotech is 543960.

  • What is the current stock price of Concord Biotech?

    As of 10-Feb-2025 the stock price of Concord Biotech is $25.50.

  • What is the current market cap of Concord Biotech?

    The current market capitalization of Concord Biotech is $2.67B.

  • What is Concord Biotech’s current revenue?

    The trailing twelve month revenue for Concord Biotech is $128M.

  • What is Concord Biotech’s annual earnings per share (EPS)?

    Concord Biotech’s EPS for 12 months was $0.38.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »